Our company news

We are working on the following new projects: • We received a contract for a phase I study with Pembrolizumab.

We are working on the following new projects: • A contract for a phase III study with Aflibercept was signed.

January We are working on the following new projects: • We have successfully passed quality control of a global company and we are finalizing a contract for data management activities in observational programs.

We are working on the following new projects: • We signed a contract for a phase III trial in patients with nasopharyngitis.

We are working on the following new projects: • We won a bidding for an adalimumab trial, phase I.

October We are working on the following new projects: • We signed a contract for medical writing activities for a phase III trial with glucosamine + chondroitin sulfate.

We are working on the following new projects: • We signed a contract for medical writing activities for a BE trial with our long-term Client.

August We are working on the following new projects: • We were awarded with medical writing activities for bioequivalence trials with Triptorelin.

We are working on the following new projects: • We were awarded with 6 bioequivalence trials with Gliclazide, Liraglutide, Vildagliptin, Dolutegravir and Empagliflozin 10 mg and 25 mg.

We are working on the following new projects: • We signed a contract for a bioequivalence trial with Edoxaban.

We are working on the following new projects: • We signed 2 contracts for bioequivalence trials with Rivaraxoban.

His report thus illustrates his awareness of the need to guard against selection bias and shows how he attempted to hold constant potential confounding factors - clinical condition, environment, and basic diet

April We are working on the following new projects: • We have been awarded several bioequivalence studies

We were awarded with several bioequivalence trials for full services activities (Umifenovir, Tadalafil, Ipidacrine, Sertraline, Silodosine).

Smooth together with Chinese colleagues hosts a seminar on European Pharma & Medical Device Regulation and Overseas Clinical Trial Strategies on 3 April. Feel free to join.